

Effect of *Cucurbita ficifolia* and Probiotic Yogurt Consumption on Blood Glucose, Lipid Profile, and Inflammatory Marker in Type 2 Diabetes

Azade Bayat, Fatemeh Azizi-Soleiman¹, Motahar Heidari-Beni², Awat Feizi³, Bijan Iraj⁴,
Reza Ghasvand, Gholamreza Askari

Department of Community Nutrition, School of Nutrition and Food Sciences, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, ¹Department of Clinical Nutrition, School of Nutrition and Food Sciences, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, ²Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran, ³Department of Biostatistics and Epidemiology, School of Health, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, ⁴Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence to:

Dr. Gholamreza Askari, Department of Community Nutrition, School of Nutrition and Food Sciences, Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: askari.mui.ac.ir

How to cite this article: Bayat A, Azizi-Soleiman F, Heidari-Beni M, Feizi A, Iraj B, Ghasvand R, et al. Effect of *cucurbita ficifolia* and probiotic yogurt consumption on blood glucose, lipid profile, and inflammatory marker in Type 2 Diabetes. Int J Prev Med 2016;7:30.

ABSTRACT

Background: Control of blood sugar, hypertension, and dyslipidemia are key factors in diabetes management. *Cucurbita ficifolia* (pumpkin) is a vegetable which has been used traditionally as a remedy for diabetes in Iran. In addition, consumption of probiotics may have beneficial effects on people with Type 2 diabetes. The aim of this study was an investigation of the effects of *C. ficifolia* and probiotic yogurt consumption alone or at the same time on blood glucose and serum lipids in diabetic patients.

Methods: Eighty eligible participants randomly were assigned to four groups: 1 - green *C. ficifolia* (100 g); 2 - probiotic yogurt (150 g); 3 - *C. ficifolia* plus probiotic yogurt (100 g *C. ficifolia* plus 150 g yogurt); and 4 - control (dietary advice) for 8 weeks. Blood pressure, glycemic response, lipid profile, and high-sensitive C-reactive protein (hsCRP) were measured before and after the intervention.

Results: Total cholesterol (TC) decreased significantly in yogurt and yogurt plus *C. ficifolia* groups (within groups $P = 0.010$, and $P < 0.001$, respectively). *C. ficifolia* plus yogurt consumption resulted in a decrease in triglyceride (TG) and an increase in high-density lipoprotein cholesterol (HDL-C) (within groups $P < 0.001$ and $P = 0.001$, respectively). All interventions led to a significant decrease in blood sugar, hemoglobin A1c (HbA1c), hsCRP, and low-density lipoprotein cholesterol (LDL-C) level within groups. Blood pressure decreased significantly in Cucurbita group and yogurt group (within groups $P < 0.001$, and $P = 0.001$ for systolic blood pressure [SBP] and $P < 0.001$, and $P = 0.004$ for diastolic blood pressure [DBP], respectively). All variables changed between groups significantly except LDL-C level.

Conclusions: Variables including TG, HDL-C, TC, fasting blood sugar, HbA1c, SBP, DBP, and hsCRP changed beneficially between groups. It seems that consumption of *C. ficifolia* and probiotic yogurt may help treatment of diabetic patients.

Keywords: Glycemic response, inflammatory marker, lipid profile, probiotic yogurt, pumpkin, Type 2 diabetes

Access this article online

Quick Response Code:



Website: www.ijpvmjournal.net/www.ijpm.ir

DOI:
10.4103/2008-7802.175455

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a chronic disease caused by insulin resistance and consequent decline in peripheral glucose uptake. Sedentary lifestyle, obesity, and unhealthy dietary behaviors are the most common risk factors of T2DM.^[1] It was estimated that diabetes prevalence was 4% in 2010 and was expected to reach 5.4% by 2025.^[2] The burden of T2DM is predicted to double in the near future. Approximately, 7.7% or 2 million adults suffer from diabetes in Iran. Diabetes prevalence has been reported 7% and 8% in Isfahan and Tehran provinces, respectively.^[3] T2DM leads to serious complications such as nervous system disorders, kidney diseases, and eye problems, thus its prevention and treatment should be considered an urgent priority.^[4] Medicinal plants have been used in the treatment of this disease as a supplementary method. There are more than 800 plants that have been utilized as an experimental treatment for DM. Their active compounds that have hypoglycemic effects included mucilage gum, glycans, flavonoids, triterpenes, and alkaloids. One of these plants that has been used traditionally in Asia is *Cucurbita ficifolia* (*Cucurbitaceae*) popularly known as pumpkin.^[5,6] Initial investigations indicated that *C. ficifolia* may reduce blood glucose and lipid profile and improve glucose tolerance.^[7] However, the mechanism of anti-diabetic action of this vegetable is unknown. Probiotic foods have live organisms which are beneficial for health. There are some evidences that probiotic foods consumption or supplementation might reduce serum cholesterol level and improve insulin sensitivity.^[8] Some studies have evaluated the favorable health effects of probiotic dairy products. They showed that probiotic yogurt had a beneficial effect on metabolic factors and health cardiovascular health parameters.^[9-12]

Since, there is little information regarding the effects of *C. ficifolia* and probiotic foods on blood glucose levels in humans, the goal of this study was to determine the effects of *C. ficifolia* and/or probiotic yogurt consumption on glycemic control, lipid profile, and inflammatory markers in Type 2 diabetic patients.

METHODS

Study design and participants

We conducted a parallel-group randomized controlled clinical trial. Type 2 diabetic patients were recruited from the Endocrinology and Metabolism Research Center, Isfahan. Eligibility criteria were age between 25 and 75 years, fasting blood sugar (FBS) more than 126 mg/dL, and controlled blood lipid without changing the drug instruction. All participants had to be no-smokers, take metformin or glibenclamide to control

blood sugar, and not to drink any kinds of alcoholic beverages. Patients were excluded if they had a history of chronic illnesses such as renal, liver, pulmonary, and heart diseases or pancreatitis, endocarditis, short bowel syndrome, and allergy. None of the participants had autoimmune disorders were pregnant or lactating mothers. Totally, 80 Type 2 diabetic patients were selected and asked to participate in the study. The study protocol was approved by the Ethics Committee at Isfahan University of Medical Sciences, and all participants completed an informed consent form. Flow chart of study participants was shown in Figure 1.

Procedures

After enrollment, the subjects were randomly assigned to one of four dietary intervention arms lasting 8 weeks. During the intervention, subjects took one of following diets: (1) *C. ficifolia* (100 g); (2) probiotic yogurt (150 g); (3) *C. ficifolia* and probiotic yogurt (100 g *C. ficifolia* plus 150 g yogurt); and (4) control (dietary advice). Patients were instructed on consuming *C. ficifolia* and yogurt at lunch. They were required to consume *C. ficifolia*. Subjects were asked not to change their dietary habits, physical activity level, or other lifestyle factors during the study. Dietary compliance was assessed by regular weekly contacts or text messages. We also took a 3-day diet recall to assure compliance and analyzed it with Nutrition-IV software, version 15 (First Databank, San Bruno, CA, USA). This clinical trial was registered at irct.ir with number IRCT2013041311763N7.

Laboratory analyses

Five milliliter of fasting blood samples were obtained at baseline and at the end of the study. Plasma and serum stored at -70°C for determination of glucose, lipids, and CRP. Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triacylglycerols were measured by autoanalyzer. The Friedewald equation was used to calculate low-density lipoprotein cholesterol (LDL-C),^[13] when plasma triglyceride (TG) concentration was <400 mg/dL. Blood glucose (glucose oxidase method)^[14] and hemoglobin A1c (HbA1c) were determined by an autoanalyzer. Serum concentrations of high sensitive C-reactive protein (hsCRP) were determined by immune turbidimetric using PARS AZMOON kit.

Statistical analysis

All quantitative variables have been reported as mean \pm standard deviation, and qualitative variables as frequency (percent). Normality of variables was evaluated using K-S test or P-P plot. For nonnormal variables, log transformation was used. One-way analysis of variance (ANOVA) and Chi-square were used to assess baseline differences among the groups. Paired *t*-test was used to evaluate the difference between baseline and final values. Further analyses were

conducted to investigate the between-group comparisons using multivariate ANOVA or multivariate analysis of covariance as appropriate. Bonferroni *post hoc* test was used for pairwise comparisons. The value $P < 0.05$ was considered as statistically significant level. Analyses were performed using SPSS 15.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

All 80 subjects completed the study (28.4 ± 2.9 y; body mass index, 23.1 ± 0.9 kg/m²). The characteristics of the patients showed no significant differences between groups [Table 1]. There was no significant difference between groups in total energy intake, macronutrient intake, and body weight at baseline. At the end of the study, no statistically significant differences between groups were observed for dietary intakes [Table 2]. Baseline values of biochemical measures were not different between groups.

After 8 weeks, there were no significant changes in TC and LDL-C in the control group, but TG increased ($P = 0.012$), and HDL-C decreased ($P = 0.034$) significantly. In all intervention groups TC decreased, but

it was significant only in yogurt and yogurt plus *C. ficifolia* groups ($P = 0.010$, and $P < 0.001$, respectively). TG declined, and HDL-C enhanced significantly in *C. ficifolia* plus yogurt group ($P < 0.001$ and $P = 0.001$, respectively). Yogurt consumption decreased LDL-C significantly ($P = 0.003$ in yogurt and $P = 0.004$ in *C. ficifolia* plus yogurt). All changes were significant between groups ($P < 0.001$) except for LDL-C.

All interventions significantly decreased FBS ($P = 0.001$ in pumpkin, $P = 0.014$ in yogurt, and $P < 0.001$ in *C. ficifolia* plus yogurt) and HbA1c ($P < 0.001$ in *C. ficifolia*, $P = 0.002$ in yogurt, and $P = 0.000$ in *C. ficifolia* plus yogurt) in comparison with control group (between group P , 0.001 and < 0.001 , respectively). HsCRP showed a significant reduction in all intervention groups ($P < 0.001$) which was more significant in *C. ficifolia* and *C. ficifolia* plus yogurt groups compared with yogurt group. At the end of the study, a statistically significant difference was seen among groups in systolic blood pressure (SBP) and diastolic blood pressure (DBP). Blood pressure decreased in *C. ficifolia* group and yogurt group significantly ($P < 0.001$, and $P = 0.001$ for SBP and $P < 0.001$, and $P = 0.004$ for DBP, respectively) [Table 3].

Table 1: Baseline characteristics of participants in all groups

Variables	Control	Green pumpkin	Yogurt	Green pumpkin plus yogurt	P
Age (year)	46.95±9.34	51.8±2.24	54.1±9.54	53.65±6.99	0.08
Sex (% male)	45	60	15	20	0.09
Height (cm)	163.05±10.36	163±10.21	158.8±7.26	160.2±7.99	0.36
Weight (kg)	79.23±14.81	76.83±10.73	72.5±12.09	71.67±9.77	0.15
BMI (kg/m ²)	29.75±4.66	28.95±3.34	28.77±4.59	27.98±4.2	0.62

BMI=Body mass index

Table 2: Comparison of nutrients intake in all groups of study

Variables	Control	Green pumpkin	Yogurt	Green pumpkin plus yogurt	P
Energy (kcal)	2059.71±494.08	2232.09±638.52	2069.53±506.12	2213.04±647.77	0.556
Carbohydrate (g)	253.87±28.69	320.68±27.78	302.63±75.03	346.92±150.67	0.131
Protein (g)	51.16±72.72	63.47±49.45	67.52±20.64	69.18±20.06	0.954
Total fat (g)	60.56±23.25	40.81±26.13	69.61±29.43	62.66±27.96	0.972
SFA (g)	10.00±5.47	10.77±3.63	11.50±5.89	12.59±5.63	0.580
MUFA (g)	13.81±14/48	11.69±6.95	11.12±4.29	15.09±7.63	0.610
PUFA (g)	13.73±10.24	13.09±11.12	10.24±4.34	13.61±5.49	0.630
Vitamin C (mg)	87.72±66.60	54.00±47.16	92.21±63.28	75.03±30.62	0.221
Vitamin D (pg)	0.30±0.54	0.25±0.63	0.56±1.04	0.62±0.94	0.507
Sodium (mg)	2038.1±878.64	2563.0±1221.48	2718.1±1819.71	2384.6±1120.14	0.527
Potassium (mg)	734.37±2662.2	2437.0±649.08	573.57±2580.9	489.37±2654.9	0.733
Calcium (mg)	790.09±230.34	798.41±336.93	772.49±355.00	832.63±357.19	0.960
Total fiber (g)	3.20±6.48	6.24±2.70	6.66±3.53	6.65±2.43	0.978
Soluble fiber (g)	0.539±0.261	0.299±0.256	0.520±0.289	0.462±0.330	0.101
Insoluble fiber (g)	3.97±3.00	2.20±1.25	2.92±1.28	3.42±2.35	0.138
Sucrose (g)	11.66±9.10	7.18±6.42	10.23±6.12	10.09±6.32	0.378
Glucose (g)	8.44±5.59	8.19±2.92	8.96±3.90	8.15±3.78	0.947

SFA=Saturated fatty acid, MUFA=Monounsaturated fatty acid, PUFA=Polyunsaturated fatty acid

Table 3: Blood pressure, fasting blood glucose, hemoglobin A1c, serum lipids, and high sensitive C-reactive protein at baseline and postintervention in the four groups

Variables	Control	Green pumpkin	Yogurt	Green pumpkin plus yogurt	P [*]
SBP (mmHg)					
Before	127.0±13.41	125.0±17.01	124.50±12.76	125.0±14.68	0.004
After	125.50±14.68	113.50±11.82	117.50±9.10	122.0±11.05	
P [*]	0.48	<0.001	0.001	0.23	
DBP (mmHg)					
Before	85.50±9.44	86.0±9.94	83.0±8.01	82.50±10.69	0.001
After	85.0±10.51	77.50±7.16	78.50±5.87	81.0±9.67	
P [*]	0.71	<0.001	0.004	0.37	
FBS (mg/dL)					
Before	145.20±41.90	156.10±43.35	148.95±47.26	180.80±68.68	0.001
After	165.50±41.34	123.95±21.98	126.25±34.01	115.0±22.40	
P [*]	0.02	0.001	0.01	<0.001	
HbA1c (%)					
Before	7.54±2.03	7.21±0.91	7.06±1.58	7.97±1.265	<0.001
After	7.55±1.87	6.41±0.78	6.49±1.33	6.40±1.18	
P [*]	0.98	<0.001	0.002	<0.001	
TC (mg/dL)					
Before	178.9±54.97	188.80±32.53	188.85±49.22	189.0±43.05	<0.001
After	189.35±46.36	168.70±35.79	165.7±42.37	150.15±40.78	
P [*]	0.29	0.053	0.01	<0.001	
TG (mg/dL)					
Before	165.20±65.58	204.05±148.23	190.65±129.11	203.70±87.50	<0.001
After	206.80±93.24	146.30±48.37	142.70±55.0	127.15±37.31	
P [*]	0.01	0.07	0.06	<0.001	
LDL-C (mg/dL)					
Before	110.66±41.68	121.14±28.62	107.63±34.97	109.03±40.43	0.150
After	106.55±29.19	95.41±28.63	93.82±27.80	92.03±31.60	
P [*]	0.56	0.003	0.057	0.004	
HDL-C (mg/dL)					
Before	44.45±9.43	37.70±7.48	44.80±10.04	40.55±9.09	<0.001
After	40.34±11.50	39.70±9.17	48.40±10.49	51.50±12.71	
P [*]	0.03	0.30	0.07	0.001	
hsCRP					
Before	1.16±0.24	1.40±0.18	1.29±0.27	1.69±0.25	<0.001
After	1.24±0.32	1.16±0.20	1.13±0.29	1.13±0.34	
P [*]	0.14	<0.001	0.006	<0.001	

*Within group comparisons based on paired t-test, *Between group comparisons based on MANOVA. DBP=Diastolic blood pressure, SBP=Systolic blood pressure, FBS=Fasting blood sugar, TC=Total cholesterol, TG=Triglyceride, HDL-C=High-density lipoprotein cholesterol, LDL-C=Low-density lipoprotein cholesterol, MANOVA=Multivariate analysis of variance, HbA1c=Hemoglobin A1c, hsCRP=High sensitive C-reactive protein

DISCUSSION

In patients with Type 2 diabetes, it appears that probiotic yogurt consumption may substantially influence TC, FBS, HbA1c, hsCRP, and blood pressure. *C. ficifolia* significantly decreased LDL-C, glycemic control, hsCRP, and blood pressure. The most favorable effects on lipid profile, FBS, HbA1c, and hsCRP were related to *C. ficifolia* plus probiotic yogurt.

A few studies on human have shown that probiotic foods may decline serum lipids and lipoproteins.^[15-17] The

only study which used probiotic yogurt showed that TC decreased in mild to moderate hyperlipidemic subjects, but the other components of lipid profile did not change.^[16] In this study, *C. ficifolia* just decreased LDL-C but animal studies revealed that it may reduce TG and increase HDL-C too.^[18-20] The most noticeable results were related to *C. ficifolia* plus yogurt, which decreased atherogenic lipids and lipoproteins and increased HDL-C. To the best of our knowledge, no study has evaluated the combination of these two foods. The amount of pectin in *C. ficifolia* is high which can increase bile salts excretion




Figure 1: Flow chart of study participants

and lipoprotein lipase activity and consequently decrease serum lipid levels.^[19] The mechanism by which probiotic yogurt cholesterol reduces cholesterol can be attributed to the removal of the cholesterol by assimilation, its incorporation into the cell membrane, deconjugating bile acids,^[21] and inhibition of hydroxy-methyl-glutaryl-CoA reductase (HMG-CoA reductase).^[22]

The results of the study in the subjects with Type 2 diabetes indicated that yogurt and *C. ficifolia* alone or in combination decreased FBS and HbA1c significantly. Previous studies in diabetic subjects and also rats have shown that blood glucose and insulin sensitivity improved after probiotic consumption.^[23] This finding contrasts the report by Mazloom *et al.* which concluded the relationship between probiotic capsule intake and FBS and insulin level.^[15] This study did not assess participants' compliance that can confound the results. The positive effects of *C. ficifolia* on glycemic control, insulin sensitivity, and glucose tolerance were reported by other researchers in animal models.^[15,24-28] This finding can be explained by *C. ficifolia* effects in terms of β -glucosidase α -amylase inhibition,^[24] and pancreas function and insulin sensitivity improvement.^[15,29] The amount of fiber in this vegetable is not enough to produce such a result,^[24] but it might be related to D-chiro inositol.^[18]

HsCRP decreased in all intervention groups significantly. Moroti *et al.*, evaluated the effects of *C. ficifolia* consumption on diabetic rats and found a reduction in CRP.^[23] They assumed that it dropped because of the flavonoid content of *C. ficifolia*. Hadisaputro *et al.* found similar findings with kefir consumption on interleukin (IL)-1 and -6.^[30] However, Mazloom *et al.* results were nonsignificant for IL-6 reduction, and they reported an increase in CRP.^[15] This inconsistency can be described by the fact that they used probiotic as a supplement in diabetic patients. The role of probiotic in inflammation reduction may possibly be associated with gut microflora modulation.^[31,32]

In this study, yogurt and *C. ficifolia* intake relative to their combination reduced SBP and DBP. Agerholm-Larsen *et al.* showed that 8 weeks intake of probiotic milk products decreased SBP significantly in

healthy obese and overweight people.^[33] Daily ingestion of the probiotic dairy such as fermented milk can reduce blood pressure in the high normal to mild hypertensive subjects.^[34] Probiotics produce angiotensin-converting enzyme peptides by microbial activity which can play a role in blood pressure reduction.^[35] It has not yet been defined any special mechanism for blood pressure lowering effect of *C. ficifolia*. As oxidative stress can lead to an increase in peripheral vascular resistance and hypertension^[36] and Cucurbita decreases lipid peroxidation index such as thiobarbituric acid reactive substances and malondialdehyde and increases glutathione activity,^[18,27] this outcome can be partly explained. However, we could find no interpretation for the lack of impact of yogurt and *C. ficifolia* combination on blood pressure.

CONCLUSIONS

Our results suggest that probiotic yogurt and *C. ficifolia* alone or together have beneficial effects on lipid profile, glycemic control, inflammation, and blood pressure in Type 2 diabetic patients. Our data confirm that concomitant use of *C. ficifolia* and yogurt has more noteworthy results in comparison with their intake alone. Variables including TG, HDL-C, TC, FBS, HbA1c, SBP, DBP, and hsCRP changed beneficially between groups. It seems that consumption of *C. ficifolia* and probiotic yogurt may help treatment of diabetic patients. Conducting more research in this area seems necessary to elucidate mechanisms and other effects.

Acknowledgements

We thank Isfahan University of medical sciences and Food Security Research Center, Isfahan University of Medical Sciences (Study project number: 392362).

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Received: 18 Aug 14 Accepted: 01 Dec 15

Published: 02 Feb 16

REFERENCES

- Kiencke S, Handschin R, von Dahlen R, Muser J, Brunner-Larocca HP, Schumann J, *et al.* Pre-clinical diabetic cardiomyopathy: Prevalence, screening, and outcome. *Eur J Heart Fail* 2010;12:951-7.
- Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010;87:4-14.
- Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghazali M, Asgari F, *et al.* Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: Methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. *BMC Public Health* 2009;9:167.
- Lutale J, Thordarson H, Sanywa A, Mafwiri M, Vetvik K, Krohn J. Diabetic retinopathy prevalence and its association with microalbuminuria and other

- risk factors in patients with type 1 and type 2 diabetes in Dar es Salaam, Tanzania. *JOECSA* 2013;15:263-7.
5. Suksomboon N, Poolsup N, Boonkaew S, Suthisang CC. Meta-analysis of the effect of herbal supplement on glycemic control in type 2 diabetes. *J Ethnopharmacol* 2011;137:1328-33.
 6. Rao MU, Sreenivasulu M, Chengaiah B, Reddy KJ, Chetty CM. Herbal medicines for diabetes mellitus: A review. *Int J PharmTech Res* 2010;2:1883-92.
 7. Quanhong L, Caili F, Yukui R, Guanghui H, Tongyi C. Effects of protein-bound polysaccharide isolated from pumpkin on insulin in diabetic rats. *Plant Foods Hum Nutr* 2005;60:13-6.
 8. Asemi Z, Zare Z, Shakeri H, Sabihi SS, Esmailzadeh A. Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. *Ann Nutr Metab* 2013;63:1-9.
 9. Mani-López E, Palou E, López-Malo A. Probiotic viability and storage stability of yogurts and fermented milks prepared with several mixtures of lactic acid bacteria. *J Dairy Sci* 2014;97:2578-90.
 10. Nabavi S, Rafraf M, Somi MH, Homayouni-Rad A, Asghari-Jafarabadi M. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. *J Dairy Sci* 2014;97:7386-93.
 11. Cruz AG, Castro WF, Faria JA, Lollo PC, Amaya-Farfán J, Freitas MQ, et al. Probiotic yogurts manufactured with increased glucose oxidase levels: Postacidification, proteolytic patterns, survival of probiotic microorganisms, production of organic acid and aroma compounds. *J Dairy Sci* 2012;95:2261-9.
 12. Lollo PC, Morato PN, Moura CS, Almada CN, Felicio TL, Esmerino EA, et al. Hypertension parameters are attenuated by the continuous consumption of probiotic Minas cheese. *Food Res Int* 2015;76:611-7.
 13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972;18:499-502.
 14. Kadish AH, Litle RL, Sternberg JC. A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. *Clin Chem* 1968;14:116-31.
 15. Mazloom Z, Yousefinejad A, Dabbaghmanesh MH. Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: A clinical trial. *Iran J Med Sci* 2013;38:38-43.
 16. Ataei-Jafari A, Tahbaz F, Alavi-Majd H, Joodaki H. Comparison of the effect of a probiotic yogurt and ordinary yogurt on serum cholesterol levels in subjects with mild to moderate hypercholesterolemia. *Iran J Diabetes Lipid Disord* 2005;4:48-3.
 17. Moroti C, Magri LF, de Rezende Costa M, Cavallini DC, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. *Lipids Health Dis* 2012;11:1-8.
 18. Díaz-Flores M, Angeles-Mejia S, Baiza-Gutman LA, Medina-Navarro R, Hernández-Saavedra D, Ortega-Camarillo C, et al. Effect of an aqueous extract of *Cucurbita ficifolia* Bouché on the glutathione redox cycle in mice with STZ-induced diabetes. *J Ethnopharmacol* 2012;144:101-8.
 19. Kazemi S, Asgari S, Mshtaqaan S, Rafeian M, Mahzouni P. Pumpkin preventive effect on diabetic indices and histopathology of the pancreas in rats with alloxan diabetes. *J Isfahan Med Sch* 2010;28:1108-117.
 20. Yoshinari O, Sato H, Igarashi K. Anti-diabetic effects of pumpkin and its components, trigonelline and nicotinic acid, on Goto-Kakizaki rats. *Biosci Biotechnol Biochem* 2009;73:1033-41.
 21. Lye HS, Kuan CY, Ewe JA, Fung WY, Liong MT. The improvement of hypertension by probiotics: Effects on cholesterol, diabetes, renin, and phytoestrogens. *Int J Mol Sci* 2009;10:3755-75.
 22. Aggarwal J, Swami G, Kumar M. Probiotics and their effects on metabolic diseases: An update. *J Clin Diagn Res* 2013;7:173-7.
 23. Moroti C, Souza Magri LF, de Rezende Costa M, Cavallini DC, Sivieri K. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. *Lipids Health Dis* 2012;11:29.
 24. Acosta-Patiño JL, Jiménez-Balderas E, Juárez-Oropeza MA, Díaz-Zagoya JC. Hypoglycemic action of *Cucurbita ficifolia* on type 2 diabetic patients with moderately high blood glucose levels. *J Ethnopharmacol* 2001;77:99-101.
 25. Alarcon-Aguilar FJ, Hernandez-Galicia E, Campos-Sepulveda AE, Xolalpa-Molina S, Rivas-Vilchis JF, Vazquez-Carrillo LI, et al. Evaluation of the hypoglycemic effect of *Cucurbita ficifolia* Bouché (*Cucurbitaceae*) in different experimental models. *J Ethnopharmacol* 2002;82:185-9.
 26. Jiang Z, Du Q. Glucose-lowering activity of novel tetrasaccharide glyceroglycolipids from the fruits of *Cucurbita moschata*. *Bioorg Med Chem Lett* 2011;21:1001-3.
 27. Xia T, Wang Q. Hypoglycaemic role of *Cucurbita ficifolia* (*Cucurbitaceae*) fruit extract in streptozotocin-induced diabetic rats. *J Sci Food Agric* 2007;87:1753-7.
 28. Yadav M, Jain S, Tomar R, Prasad GB, Yadav H. Medicinal and biological potential of pumpkin: An updated review. *Nutr Res Rev* 2010;23:184-90.
 29. Kazemi S, Asgari S, Mshtaqaan S, Rafeian M, Shklabady R. Pumpkin preventive effect on serum lipid levels in alloxan-induced diabetic mice. *Univ J Med Sci* 2011;9:1108-17.
 30. Hadisaputro S, Djokomoeljanto RR, Judiono, Soesatyo MH. The effects of oral plain kefir supplementation on proinflammatory cytokine properties of the hyperglycemia Wistar rats induced by streptozotocin. *Acta Med Indones* 2012;44:100-4.
 31. Jeppsson B, Mangell P, Thorlacius H. Use of probiotics as prophylaxis for postoperative infections. *Nutrients* 2011;3:604-12.
 32. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: A role in the treatment of intestinal infection and inflammation? *Gut* 2002;50 Suppl 3:III54-9.
 33. Agerholm-Larsen L, Raben A, Haulrik N, Hansen AS, Manders M, Astrup A. HYPERLINK "<http://www.ncbi.nlm.nih.gov/pubmed/10745279>". Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. *Eur J Clin Nutr* 2000;54:288-97.
 34. Lye HS, Kuan CY, Ewe JA, Fung WY, Liong MT. The improvement of hypertension by probiotics: Effects on cholesterol, diabetes, renin, and phytoestrogens. *Int J Molec Sc* 2009;10:3755-75.
 35. Gobetti M, Ferranti P, Smacchi E, Goffredi F, Addeo F. Production of Angiotensin-I-converting-enzyme-inhibitory peptides in fermented milks started by *Lactobacillus delbrueckii* subsp. *bulgaricus* SSI and *Lactococcus lactis* subsp. *cremoris* FT4. *APPL ENVIRON MICROB* 2000;66:3898-904.
 36. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature molecular and cellular mechanisms. *Hypertension* 2003;42:1075-81.